VeriSIM Life
VeriSIM Life is a biotechnology company focused on accelerating drug discovery and development through AI-driven, multi-disciplinary quantitative methods. Their mission is to eliminate inaccuracy and waste in the drug development process by predicting patient outcomes more effectively. The company's core platform, BIOiSIM®, utilizes a decision engine that combines chemical and biological modeling with AI and ML to provide a Translational Index™ that predicts drug efficacy and safety. A key product is AtlasGEN™ Novel Drug Designer, which identifies new molecules, evaluates their clinical safety and effectiveness, and leverages the Translational Index™ to reduce the time and cost of drug development. VeriSIM Life aims to improve the success rate of drugs entering clinical trials, reduce animal testing, and ultimately bring better therapies to market faster. They also operate PulmoSIM Therapeutics, a wholly-owned brand focused on identifying licensable drug candidates for preclinical translation.
VeriSIM Life
VeriSIM Life is a biotechnology company focused on accelerating drug discovery and development through AI-driven, multi-disciplinary quantitative methods. Their mission is to eliminate inaccuracy and waste in the drug development process by predicting patient outcomes more effectively. The company's core platform, BIOiSIM®, utilizes a decision engine that combines chemical and biological modeling with AI and ML to provide a Translational Index™ that predicts drug efficacy and safety. A key product is AtlasGEN™ Novel Drug Designer, which identifies new molecules, evaluates their clinical safety and effectiveness, and leverages the Translational Index™ to reduce the time and cost of drug development. VeriSIM Life aims to improve the success rate of drugs entering clinical trials, reduce animal testing, and ultimately bring better therapies to market faster. They also operate PulmoSIM Therapeutics, a wholly-owned brand focused on identifying licensable drug candidates for preclinical translation.
TL;DR
Founded: 2017
Headquarters: San Francisco, CA
Core product: BIOiSIM — AI + mechanistic biosimulation platform
Series A: $15M (Jan 2022, led by Morpheus Ventures)
Total funding (reported): Over $21M
Company Overview
Problem Domain
De-risking early-stage drug discovery and development through predictive in silico modeling and translational intelligence.
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
$15,000,000
Announced as an oversubscribed Series A with participation from additional investors.
Investor Signal
“Includes participation from corporate and specialized biotech investors (e.g., Intel Capital, Debiopharm Innovation Fund, Colorcon Ventures) alongside VC firms.”